Awakn Life Sciences’ Post

Very Important Global PSA to whom/those it may concern:~ get all this VERY ESSENTIAL "#NuclearMedicine therapeutics" ready and primed to go as recommended over the years. You will most likely be needing them soon/@ THE NEXT AVAILABLE OPPORTUNITY. Be very strategic, clinical & synchronized WHEN administering #TheTreatment. Thanks. cc: Total Destruction MOU of INCURABLE #SatanicCriminalBunch, etc.

What Are @Digital Therapeutics? Here is an article with the list of Top 10 Companies in #digitaltherapeutics in 2024. Read here: https://lnkd.in/dYTdMti4

What's In The Vial?! A [Brief] Meditation On Control Strategy Gregory Troiano from Sanofi and April Sena from Life Edit Therapeutics addressed an audience question on whether the crucial aspect lies in the contents of the vial or the production process itself. Watch the clip (2:27): https://lnkd.in/eYDrZqAw #AdvancingRNA #rawmaterials #mrna #supplychain

In this K-Cast, Diana Brixner, PhD, FAMCP, explores how the US FDA and industry associations define, identify and evaluate digital therapeutics, including nonprescription digital tools and interventions. Watch the episode here: https://bit.ly/3VyfxKV #ManagedCare #DigitalHealth Diana Brixner

Very Important Global PSA to whom/those it may concern:~ get all this VERY ESSENTIAL "#NuclearMedicine therapeutics" ready and primed to go as recommended over the years. You will most likely be needing them soon/@ THE NEXT AVAILABLE OPPORTUNITY. Be very strategic, clinical & synchronized WHEN administering #TheTreatment. Thanks. cc: Total Destruction MOU of INCURABLE #SatanicCriminalBunch, etc.

Tryp Therapeutics Ltd (ASX:TYP, OTC:TYPTF) CEO Jason Carroll joins Proactive’s Tylah Tully to talk through $6 million the company has secured through a strategic placement of 300 million new shares at $0.02 each. The placement was supported by new and existing stakeholders, including #cornerstoneinvestors, the #MerchantBiotechFund and Dr Daniel Tillett, who will join the board as a non-executive director. Key shareholders and company executives, including Carroll himself, also participated. The funds will facilitate the accelerated #clinicaldevelopment of #TRP8803, an #IVinfusedpsilocin formulation designed to address limitations associated with #oralpsilocybin dosing. Benefits of TRP-8803 include faster onset, more controlled dosing and shorter intervention times. This aligns with Tryp’s ongoing efforts to explore the compound’s therapeutic potential in treating various conditions. Watch at #Proactive #ProactiveInvestors #psilocybin #psilocin #ASX #biotech http://ow.ly/YF8o105Nm5G

The hereditary angioedema therapeutics market size is expected to see rapid growth in the next few years. It will grow to $13.47 billion in 2028 at a compound annual growth rate (CAGR) of 18.8%. https://lnkd.in/gwmKbFZY #marketresearch #marketintelligence #marketreport #industryanalysis #TheBusinessResearchCompany #TBRC #GlobalMarketModel

Check out our latest newsletter below + subscribe for quarterly updates related to pandemic preparedness and the 100DM ⬇

Our Avacta Therapeutics Outlook reviews the science & opportunity behind the pre|CISION platform & peptide-drug conjugate pipeline, which has the potential to target highly potent drugs to the TME expanding their reach & limiting systemic tox. Pipeline progress & Dx divestment represent value-inflection points #AVCT https://lnkd.in/dxcu2fT

New episode alert! Join us in uncovering the mysteries of rare diseases and pharmacogenomics with Brenna Carey from University of Cincinnati Online. Learn about diagnostics, therapeutics, and the latest trends in drug development. #TalkingTechniques Check it out! >>> https://bit.ly/3SEDM70